Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Bufuralol Hydrochloride: β-Adrenergic Receptor Antagonist...

    2026-04-02

    Bufuralol Hydrochloride: β-Adrenergic Receptor Antagonist for Cardiovascular Research

    Executive Summary: Bufuralol hydrochloride (CAS 60398-91-6) is a non-selective β-adrenergic receptor antagonist, demonstrating partial intrinsic sympathomimetic activity and membrane-stabilizing effects in vitro (Saito et al., 2025). This compound induces tachycardia in catecholamine-depleted animal models, confirming partial agonist behavior under specific physiological conditions. Bufuralol hydrochloride offers prolonged inhibition of exercise-induced heart rate elevation, rivaling propranolol (APExBIO). Its unique profile enables advanced cardiovascular pharmacology research, especially in β-adrenergic modulation studies. Reliable application depends on precise concentration control, validated models, and robust benchmarking against established β-blockers.

    Biological Rationale

    The sympathetic nervous system regulates cardiac function through β-adrenergic receptor signaling. Dysregulation is implicated in cardiovascular diseases such as hypertension and tachyarrhythmia (Redefining Cardiovascular Pharmacology). Bufuralol hydrochloride provides a tool for dissecting these pathways by blocking β-adrenoceptors non-selectively, while retaining partial agonist effects. This duality allows for nuanced modulation of heart rate, contractility, and arrhythmic potential. Recent advances in human induced pluripotent stem cell (hiPSC)-derived models, including intestinal and cardiac organoids, enable more human-relevant pharmacokinetic and pharmacodynamic studies (Saito et al., 2025). Bufuralol's stability, solubility, and pharmacological profile make it suitable for these modern experimental systems.

    Mechanism of Action of Bufuralol (hydrochloride)

    Bufuralol hydrochloride binds non-selectively to β1- and β2-adrenergic receptors, inhibiting catecholamine-induced stimulation of adenylate cyclase. Unlike pure antagonists, Bufuralol exhibits partial intrinsic sympathomimetic activity (ISA), meaning it can weakly stimulate β-adrenoceptors in the absence of endogenous agonists (Bufuralol Hydrochloride: Advancing β-Adrenergic Research). This property is evidenced by tachycardia induction in animal models with depleted catecholamines. In vitro, Bufuralol demonstrates membrane-stabilizing activity, further distinguishing it from other β-blockers. Its pharmacological effects are dose-dependent, with inhibitory concentration (IC50) values varying by tissue and species. Prolonged inhibition of exercise-induced heart rate elevation has been demonstrated clinically, comparable to propranolol but with distinct partial agonist effects (APExBIO).

    Evidence & Benchmarks

    • Bufuralol hydrochloride (C16H23NO2·HCl, MW 297.8) is a crystalline solid, soluble up to 15 mg/ml in ethanol and dimethyl formamide, and 10 mg/ml in DMSO (APExBIO, product page).
    • It inhibits β-adrenergic receptor-mediated cAMP generation in vitro in a dose-dependent fashion (Saito et al., 2025).
    • Bufuralol induces tachycardia in animal models with depleted catecholamine stores, confirming partial agonism (APExBIO, product page).
    • In human cardiovascular studies, it provides prolonged inhibition of exercise-induced heart rate elevation, with efficacy comparable to propranolol (Bufuralol Hydrochloride: Non-Selective β-Adrenergic Recep...).
    • Bufuralol's membrane-stabilizing effects have been validated in vitro using hiPSC-derived organoids, highlighting its utility in modern pharmacokinetic models (Saito et al., 2025).
    • Compared to Caco-2 cells, hiPSC-derived intestinal organoids more accurately reflect human drug metabolism and transporter function for compounds like Bufuralol (Saito et al., 2025).

    This article extends prior coverage such as Bufuralol Hydrochloride: Advancing β-Adrenergic Research ... by providing updated benchmarks and integrating translational evidence from hiPSC-derived models, which were not previously detailed.

    Applications, Limits & Misconceptions

    Bufuralol hydrochloride is widely used in:

    • Cardiac function assays and β-adrenergic modulation studies
    • Animal model research on tachycardia, hypertension, and arrhythmia
    • Evaluation of drug metabolism and transporter activity using hiPSC-derived organoids
    • Comparative studies with traditional β-blockers (e.g., propranolol) for heart rate control
    • Pharmacokinetic profiling of new compounds in human-relevant in vitro systems

    However, users must recognize methodological boundaries and avoid common misconceptions.

    Common Pitfalls or Misconceptions

    • Not a pure antagonist: Bufuralol's partial intrinsic sympathomimetic activity can confound results if interpreted as a pure β-blocker response.
    • Species-specific effects: Results from animal models may not translate directly to human systems due to interspecies differences in β-adrenoceptor subtypes and metabolism (Saito et al., 2025).
    • Stability limitations: Bufuralol hydrochloride solutions are not recommended for long-term storage; use fresh solutions for reproducibility (APExBIO).
    • Cell model selection: Caco-2 cells may underrepresent intestinal drug metabolism compared to hiPSC-derived organoids; select appropriate models for pharmacokinetic studies.
    • Solubility constraints: Careful attention to solvent and concentration is required to avoid precipitation and ensure proper dosing in experimental setups.

    Workflow Integration & Parameters

    Optimal use of Bufuralol hydrochloride in cardiovascular and β-adrenergic modulation research involves:

    • Preparation of stocks at ≤15 mg/ml in ethanol or DMF; ≤10 mg/ml in DMSO
    • Storage as a dry solid at -20°C; avoid storing solutions for extended periods (APExBIO)
    • Application in hiPSC-derived organoid models for drug absorption, metabolism, and transporter studies (Saito et al., 2025)
    • Inclusion in cardiac function assays to benchmark β-blocker efficacy and partial agonist effects
    • Contextual comparison with established β-blockers (e.g., propranolol) to delineate unique partial sympathomimetic properties

    For expanded protocols and comparative analysis, see Bufuralol Hydrochloride: Unraveling β-Adrenergic Modulati..., which this article extends by mapping solubility, storage, and model-specific parameters for translational research.

    Conclusion & Outlook

    Bufuralol hydrochloride, provided by APExBIO, is a validated, non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity. Its membrane-stabilizing and partial agonist properties make it indispensable for modern cardiovascular pharmacology research, especially in human-relevant hiPSC-derived organoid systems. Careful consideration of storage, solubility, and experimental context ensures reproducible and interpretable results. Ongoing advances in organoid and stem cell technologies will further clarify Bufuralol's translational potential in cardiovascular disease modeling and drug discovery (Saito et al., 2025).

    For product specifications, validated protocols, and ordering, see the Bufuralol (hydrochloride) product page (C5043).